Sun Hairong, Zhao Feiyan, Liu Yuanyuan, Ma Teng, Jin Hao, Quan Keyu, Leng Bing, Zhao Junwu, Yuan Xiaoling, Li Zhenguang, Li Fang, Kwok Lai-Yu, Zhang Shukun, Sun Zhihong, Zhang Jinbiao, Zhang Heping
Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering; Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs; Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, 010018, China.
Department of neurology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, 264200, China.
NPJ Parkinsons Dis. 2022 May 24;8(1):62. doi: 10.1038/s41531-022-00327-6.
Parkinson's disease (PD) is mainly managed by pharmacological therapy (e.g., Benserazide and dopamine agonists). However, prolonged use of these drugs would gradually diminish their dopaminergic effect. Gut dysbiosis was observed in some patients with PD, suggesting close association between the gut microbiome and PD. Probiotics modulate the host's gut microbiota beneficially. A 3-month randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the beneficial effect of probiotic co-administration in patients with PD. Eighty-two PD patients were recruited and randomly divided into probiotic [n = 48; Bifidobacterium animalis subsp. lactis Probio-M8 (Probio-M8), Benserazide, dopamine agonists] and placebo (n = 34; placebo, Benserazide, dopamine agonists) groups. Finally, 45 and 29 patients from Probio-M8 and placebo groups provided complete fecal and serum samples for further omics analysis, respectively. The results showed that Probio-M8 co-administration conferred added benefits by improving sleep quality, alleviating anxiety, and gastrointestinal symptoms. Metagenomic analysis showed that, after the intervention, there were significantly more species-level genome bins (SGBs) of Bifidobacterium animalis, Ruminococcaceae, and Lachnospira, while less Lactobacillus fermentum and Klebsiella oxytoca in Probio-M8 group (P < 0.05). Interestingly, Lactobacillus fermentum correlated positively with the scores of UPDRS-III, HAMA, HAMD-17, and negatively with MMSE. Klebsiella oxytoca correlated negatively with feces hardness. Moreover, co-administering Probio-M8 increased SGBs involved in tryptophan degradation, gamma-aminobutyric acid, short-chain fatty acids, and secondary bile acid biosynthesis, as well as serum acetic acid and dopamine levels (P < 0.05). Taken together, Probio-M8 synergized with the conventional regimen and strengthened the clinical efficacy in managing PD, accompanied by modifications of the host's gut microbiome, gut microbial metabolic potential, and serum metabolites.
帕金森病（PD）主要通过药物治疗（如苄丝肼和多巴胺激动剂）进行管理。然而，长期使用这些药物会逐渐降低其多巴胺能效应。在一些帕金森病患者中观察到肠道微生物群失调，这表明肠道微生物群与帕金森病之间存在密切关联。益生菌可有益地调节宿主的肠道微生物群。开展了一项为期3个月的随机、双盲、安慰剂对照临床试验，以研究联合使用益生菌对帕金森病患者的有益作用。招募了82名帕金森病患者，并将其随机分为益生菌组[n = 48；动物双歧杆菌乳酸亚种Probio-M8（Probio-M8）、苄丝肼、多巴胺激动剂]和安慰剂组[n = 34；安慰剂、苄丝肼、多巴胺激动剂]。最后，Probio-M8组和安慰剂组分别有45名和29名患者提供了完整的粪便和血清样本用于进一步的组学分析。结果表明，联合使用Probio-M8通过改善睡眠质量、缓解焦虑和胃肠道症状带来了额外益处。宏基因组分析表明，干预后，Probio-M8组中动物双歧杆菌、瘤胃球菌科和毛螺菌科的物种水平基因组箱（SGB）显著增多，而发酵乳杆菌和产酸克雷伯菌减少（P < 0.05）。有趣的是，发酵乳杆菌与统一帕金森病评定量表第三部分（UPDRS-III）、汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表17项版本（HAMD-17）评分呈正相关，与简易精神状态检查表（MMSE）评分呈负相关。产酸克雷伯菌与粪便硬度呈负相关。此外，联合使用Probio-M8增加了参与色氨酸降解、γ-氨基丁酸、短链脂肪酸和次级胆汁酸生物合成的SGB，以及血清乙酸和多巴胺水平（P < 0.05）。综上所述，Probio-M8与传统治疗方案协同作用，增强了帕金森病管理的临床疗效，同时伴随着宿主肠道微生物群、肠道微生物代谢潜力和血清代谢物的改变。
